Persistence of myelofibrosis treated with ruxolitinib : biology and clinical implications
Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called 'driver' mutations that lead to activation of JAK2. Ruxolitinib, and other JAK2 inhibitors in clinical use, provide clinical benefit but do not have a major impact on the abnormal hematopoietic clone. This phenomenon is termed 'persistence', in contrast to usual patterns of resistance. Multiple groups have shown that type 1 inhibitors of JAK2, which bind the active conformation of the enzyme, lead to JAK2 becoming resistant to degradation with consequent accumulation of phospho-JAK2. In turn, this can lead to exacerbation of inflammatory manifestations when the JAK inhibitor is discontinued, and it may also contribute to disease persistence. The ways in which JAK2 V617F and CALR mutations lead to activation of JAK-STAT signaling are incompletely understood. We summarize what is known about pathological JAK-STAT activation in myelofibrosis and how this might lead to future novel therapies for myelofibrosis with greater disease-modifying potential.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
---|---|
Enthalten in: |
Haematologica - 106(2021), 5 vom: 01. Mai, Seite 1244-1253 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ross, David M [VerfasserIn] |
---|
Links: |
---|
Themen: |
82S8X8XX8H |
---|
Anmerkungen: |
Date Completed 27.05.2021 Date Revised 31.05.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3324/haematol.2020.262691 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320347206 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320347206 | ||
003 | DE-627 | ||
005 | 20231225173400.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3324/haematol.2020.262691 |2 doi | |
028 | 5 | 2 | |a pubmed24n1067.xml |
035 | |a (DE-627)NLM320347206 | ||
035 | |a (NLM)33472356 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ross, David M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Persistence of myelofibrosis treated with ruxolitinib |b biology and clinical implications |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.05.2021 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called 'driver' mutations that lead to activation of JAK2. Ruxolitinib, and other JAK2 inhibitors in clinical use, provide clinical benefit but do not have a major impact on the abnormal hematopoietic clone. This phenomenon is termed 'persistence', in contrast to usual patterns of resistance. Multiple groups have shown that type 1 inhibitors of JAK2, which bind the active conformation of the enzyme, lead to JAK2 becoming resistant to degradation with consequent accumulation of phospho-JAK2. In turn, this can lead to exacerbation of inflammatory manifestations when the JAK inhibitor is discontinued, and it may also contribute to disease persistence. The ways in which JAK2 V617F and CALR mutations lead to activation of JAK-STAT signaling are incompletely understood. We summarize what is known about pathological JAK-STAT activation in myelofibrosis and how this might lead to future novel therapies for myelofibrosis with greater disease-modifying potential | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Pyrazoles |2 NLM | |
650 | 7 | |a Pyrimidines |2 NLM | |
650 | 7 | |a ruxolitinib |2 NLM | |
650 | 7 | |a 82S8X8XX8H |2 NLM | |
650 | 7 | |a Janus Kinase 2 |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
700 | 1 | |a Babon, Jeffrey J |e verfasserin |4 aut | |
700 | 1 | |a Tvorogov, Denis |e verfasserin |4 aut | |
700 | 1 | |a Thomas, Daniel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 106(2021), 5 vom: 01. Mai, Seite 1244-1253 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
773 | 1 | 8 | |g volume:106 |g year:2021 |g number:5 |g day:01 |g month:05 |g pages:1244-1253 |
856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2020.262691 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 106 |j 2021 |e 5 |b 01 |c 05 |h 1244-1253 |